On July 6, the "Keeping Upright and Innovating Towards the Future • Research on TCM Collateral Diseases" was jointly sponsored by the Shijiazhuang High-tech Industrial Development Zone Management Committee, the Hebei Pharmaceutical Association, the Hebei Pharmaceutical Industry Association, and the World Federation of Chinese Medicine Societies Professional Committee of Collateral Diseases. The Summit Forum on Transformation of Innovative Achievements was held.
Zhang Boli, Cong Bin, Zhang Yun, Yang Baofeng, Yu Jinming, Tian Jinzhou, Wu Yiling and other academicians of the two academies, as well as Li Diangui, a master of traditional Chinese medicine, and well-known experts and scholars in the field of traditional Chinese medicine from all over the country gathered online and offline to focus on collateral diseases Conduct in-depth exchanges on important achievements in theoretical inheritance, innovation and transformation.
Zhang Boli, academician of the Chinese Academy of Engineering and winner of the national honorary title of "People's Hero", Liu Xiaohan, chairman of the Hebei Pharmaceutical Association and secretary of the Party Branch of the Hebei Pharmaceutical Industry Association, etc. delivered important speeches, expressing that the theoretical research and innovative results of TCM collateral diseases are transformed into promotion The construction of traditional Chinese medicine scientific and technological innovation system and the development of traditional Chinese medicine have provided useful reference.
Academician Zhang Boli delivered a speech at the meeting.
In his speech, Academician Zhang Boli pointed out that the theory of collateral diseases is an important achievement of the modernization of traditional Chinese medicine and a model for the inheritance and innovation of traditional Chinese medicine.
The theoretical system of collateral disease systematically constructed by Academician Wu Yiling has clarified the diagnostic criteria, scope of application and modern biological mechanism. Under the guidance of collateral disease theory, Tongxinluo, Shensong Yangxin, Qiliqiangxin, Lianhua Qingwen have been developed It has also conducted a series of strict evidence-based medical evaluations, and has achieved good results in the prevention and treatment of major clinical diseases.
The holding of the TCM Collateral Disease Research and Innovation Achievement Transformation Summit Forum is of great significance for how to better apply the collateral disease theory to the prevention and treatment of major diseases, so as to serve the masses.
In the academician salon session, the academicians exchanged views on the research of TCM collateral diseases and the transformation of innovative achievements.
Systematically construct the theoretical system of collateral diseases and establish a new discipline of TCM collateral diseases
Inheriting, innovating and developing traditional Chinese medicine is an important part of the cause of socialism with Chinese characteristics in the new era and a major event in the great rejuvenation of the Chinese nation.
Collateral disease is one of the typical representatives of traditional Chinese medicine inheritance and innovation. The theory of collateral disease in traditional Chinese medicine is an academic topic that Academician Wu Yiling has systematically studied since the 1970s.
Through more than 40 years of hard work and innovation, the scattered records of "collateral disease", which has lasted for nearly three thousand years in the history of Chinese medicine, have been sorted, summarized and refined into a clear, rich and instructive modern major and intractable disease. A systems theory of therapeutic value.
The framework of "three-dimensional network system" is proposed, which is the starting point to systematically study the physiological functions of collaterals and the pathogenesis, pathogenesis, syndrome differentiation and treatment of collateral diseases. and its complications, tumors, influenza and other diseases that the ancients called collateral diseases in traditional Chinese medicine clinical syndrome differentiation and treatment methods, published the monograph "Collateral Diseases"; for the first time established the theory of collaterals to guide the prevention and treatment of vascular diseases, and opened up the treatment of vascular diseases by dredging collaterals. An effective new way of microvascular disease, published the monograph "Theory of Context"; systematically explained the occurrence, development law, basic pathological changes, clinical syndrome characteristics and syndrome differentiation of qi and collateral diseases, and effectively guided modern major diseases such as neurological, endocrine, and immune diseases. treatment, published the monograph "Qi Luo Lun".
Collateral Diseases has become an innovative textbook for medical colleges and universities across the country in the new century, and courses are offered in more than 40 colleges and universities at home and abroad.
Medical colleges in Singapore and the United States offer the English course of "Collateral Diseases", and set up a number of academic exchange platforms at home and abroad, such as the "Taiwan Association of Led Diseases", "Canadian Association of Led Diseases", "European Association of Led Diseases", "American Association of Led Diseases" and other domestic and foreign academic exchange platforms. .
"Research on Collateral Disease Theory and Its Application" won the second prize of National Science and Technology Progress Award.
The "Traditional Chinese Medicine Diagnosis and Treatment Method for Collateral Diseases", with Academician Wu Yiling as the inheritor, was selected into the national intangible cultural heritage list.
The theory of collateral disease guides the research and development of patented new drugs and provides new options for clinical treatment
In recent years, the development of traditional Chinese medicine has been highly valued by the Party Central Committee and the State Council. The theoretical breakthrough is the cornerstone of the transformation of traditional Chinese medicine into productive forces and industrialization.
Under the guidance of collateral disease theory, 13 innovative patented traditional Chinese medicines have been developed. The products cover six categories of diseases with high incidence of cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors, neuropsychiatric diseases, and urinary system diseases, forming Tongxinluo. Capsules, Shensong Yangxin Capsules, Qili Qiangxin Capsules, Lianhua Qingwen Capsules (granules), Jinlida Granules and other effective medicines for cardiovascular and cerebrovascular diseases, respiratory diseases, and diabetes, make hundreds of millions of people every year. Take benefit.
In the past two years, Lianhua Qingwen has played an important role in the global epidemic prevention and control work. So far, it has been approved for listing in nearly 30 countries and regions around the world.
Approved for new coronary pneumonia indications in Kuwait, Laos and other countries; selected into the white list of anti-epidemic drugs issued by the Ministry of Health of Uzbekistan; approved to enter the designated hospitals for new coronary pneumonia in Thailand and Cambodia, and selected into the home treatment plan for patients with mild new coronary pneumonia issued by the Ministry of Health of Cambodia , which is the first time that a Chinese drug has been selected as a treatment plan for new coronary pneumonia in overseas countries.
Tongxinluo Capsules, Yangzheng Xiaoji Capsules and other varieties have been registered and sold in South Korea, Vietnam, Canada, Singapore, Indonesia and other countries, and Tongxinluo Capsules have entered the Vietnam National Medical Insurance Catalog.
The project "Construction of TCM Context Theory and Its Guidance for Prevention and Treatment of Microvascular Diseases", which covers three collateral-draining drugs, namely Tongxinluo Capsule, Shensong Yangxin Capsule, and Qili Qiangxin Capsule, won the first prize of National Science and Technology Progress Award in 2019. This is the only first prize of the National Science and Technology Progress Award in the field of medicine and health in my country.
This award proves the clinical efficacy of dredging drugs in the prevention and treatment of cardiovascular and cerebrovascular diseases, and also illustrates the charm of the combination of traditional Chinese medicine and modern technology.
This research project clarifies that the common mechanism of cardiovascular and cerebrovascular diseases, diabetic nephropathy and other intractable diseases that seriously endanger human health is microvascular disease, and the protection of microvascular endothelial cells is the core mechanism for the treatment of microvascular disease. National 973 plan project acceptance expert The group agreed that the project "has made a major breakthrough in the treatment of microvascular lesions with traditional Chinese medicine".
This project uses internationally recognized evidence-based medical research methods to carry out a large number of clinical trials to solve major problems in the international medical community - Tongxinluo Capsule solves the world medical problem of acute myocardial infarction without reflow; Shensong Yangxin Capsule is for cardiac insufficiency. The treatment of ventricular premature beats provides a new drug, which fills the gap of drug treatment for both the speed and slowness of sinus bradycardia with ventricular premature beats and the integration of rhythm regulation; Qili Qiangxin Capsules significantly improve the clinical treatment effect of chronic heart failure.
The national 973 plan project acceptance expert group said: This research "created a new model of academic innovation and transformation of traditional Chinese medicine that integrates 'theory + clinical + new drugs + experiment + evidence-based'. The combination of traditional theoretical innovation of traditional Chinese medicine and modern science and technology has produced significant The original achievements have made a demonstration for the inheritance and innovative development of traditional Chinese medicine.”
This conference conducted in-depth exchanges on the theoretical research on collateral diseases and a series of innovative achievements, which provided new perspectives and new ideas for the theoretical innovation of traditional Chinese medicine.
Inherit the essence, keep upright and innovate.
In the future, the research of TCM collateral diseases and the transformation of a series of innovative achievements will surely promote the development of TCM into a new era.